BiotechTube

AZD6140 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Blood Flow Speed

Conditions

Blood Flow Speed, Coronary Flow Velocity

Trial Timeline

Dec 1, 2010 → Apr 1, 2011

NCT ID
NCT01226602

About AZD6140 + Placebo

AZD6140 + Placebo is a phase 1 stage product being developed by AstraZeneca for Blood Flow Speed. The current trial status is completed. This product is registered under clinical trial identifier NCT01226602. Target conditions include Blood Flow Speed, Coronary Flow Velocity.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01226602Phase 1Completed

Competing Products

20 competing products in Blood Flow Speed

See all competitors
ProductCompanyStageHype Score
micafungin + voriconazoleAstellas PharmaApproved
85
CefiderocolShionogiPhase 2
52
Bunazosin + Doxazosin + ValsartinEisaiApproved
85
PegfilgrastimKyowa KirinPhase 2
52
epoetin alfaJohnson & JohnsonPhase 2/3
65
epoetin alfaJohnson & JohnsonPhase 2/3
65
epoetin alfaJohnson & JohnsonPhase 2
52
Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3
77
NKTR-118 + moxifloxacin + PlaceboAstraZenecaPhase 1
33
MEDI-551AstraZenecaPhase 1
33
Ecallantide + Cyklokapron(R)MerckPhase 2
52
DaptomycinMerckPhase 2
52
ecallantide + placeboMerckPhase 2
52
MK0859MerckPhase 1
33
Ecallantide + PlaceboMerckPhase 2
52
HSC835NovartisPhase 2
52
AliskirenNovartisApproved
85
Aliskiren and HCTZNovartisApproved
85
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo AmlodipineNovartisPhase 2
52
Darbepoetin alfaAmgenPhase 1/2
40

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85